- Home
- AJG vs ZTS Comparison
AJG vs ZTS Comparison
Compare AJG & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AJG
- ZTS
- Stock Information
- Founded
- AJG 1927
- ZTS 1952
- Country
- AJG United States
- ZTS United States
- Employees
- AJG N/A
- ZTS N/A
- Industry
- AJG Specialty Insurers
- ZTS Biotechnology: Pharmaceutical Preparations
- Sector
- AJG Finance
- ZTS Health Care
- Exchange
- AJG Nasdaq
- ZTS Nasdaq
- Market Cap
- AJG 80.9B
- ZTS 73.2B
- IPO Year
- AJG N/A
- ZTS 2013
- Fundamental
- Price
- AJG $313.18
- ZTS $148.53
- Analyst Decision
- AJG Hold
- ZTS Buy
- Analyst Count
- AJG 13
- ZTS 8
- Target Price
- AJG $309.46
- ZTS $204.00
- AVG Volume (30 Days)
- AJG 1.5M
- ZTS 2.9M
- Earning Date
- AJG 07-31-2025
- ZTS 08-05-2025
- Dividend Yield
- AJG 0.83%
- ZTS 1.35%
- EPS Growth
- AJG 34.49
- ZTS 7.32
- EPS
- AJG 6.66
- ZTS 5.57
- Revenue
- AJG $11,243,500,000.00
- ZTS $9,286,000,000.00
- Revenue This Year
- AJG $28.59
- ZTS $3.45
- Revenue Next Year
- AJG $23.19
- ZTS $6.16
- P/E Ratio
- AJG $47.05
- ZTS $26.66
- Revenue Growth
- AJG 11.57
- ZTS 6.32
- 52 Week Low
- AJG $267.00
- ZTS $139.70
- 52 Week High
- AJG $351.23
- ZTS $200.33
- Technical
- Relative Strength Index (RSI)
- AJG 43.99
- ZTS 29.66
- Support Level
- AJG $305.39
- ZTS $156.26
- Resistance Level
- AJG $315.57
- ZTS $161.77
- Average True Range (ATR)
- AJG 5.64
- ZTS 3.34
- MACD
- AJG 0.18
- ZTS -0.82
- Stochastic Oscillator
- AJG 43.62
- ZTS 6.63
About AJG Arthur J. Gallagher & Co.
Founded in 1927 as a one-person agency, Gallagher's primary business is insurance brokerage, with a focus on serving middle-market companies. The company's risk management segment provides third-party claims adjustment to companies that choose to self-insure. Gallagher has about 56,000 employees and generates about a third of its revenue internationally, primarily in Australia, Canada, New Zealand, and the UK.
About ZTS Zoetis Inc.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its us business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.